Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective

Moeckli, Beat; Majno, Pietro; Orci, Lorenzo A.; Peloso, Andréa; Toso, Christian

doi:10.1055/s-0041-1723032

Cited by 11 publications

(5 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LT is a definitive treatment option for HCC, but the favorable prognosis of LT for HCC relies on the precise selection of good candidates 16 , 17 . Since Mazzaferro and colleagues 18 – 23 proposed the Milan criteria for LT in patients with HCC, several studies have suggested various other patient selection criteria to achieve optimal outcomes in these patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China

Chen,

Yang,

Gao

et al. 2024

Cancer Biol Med

View full text Add to dashboard Cite

Objective: Sex-specific differences are observed in various liver diseases, but the influence of sex on the outcomes of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains to be determined. This study is the first Chinese nationwide investigation of the role of sex in post-LT outcomes in patients with HCC. Methods: Data for recipients with HCC registered in the China Liver Transplant Registry between January 2015 and December 2020 were analyzed. The associations between donor, recipient, or donor-recipient transplant patterns by sex and the post-LT outcomes were studied with propensity score matching (PSM). The survival associated with different sex-based donor-recipient transplant patterns was further studied. Results: Among 3,769 patients enrolled in this study, the 1-, 3-, and 5-year overall survival (OS) rates of patients with HCC after LT were 96.1%, 86.4%, and 78.5%, respectively, in female recipients, and 95.8%, 79.0%, and 70.7%, respectively, in male recipients after PSM (P = 0.009). However, the OS was comparable between recipients with female donors and male donors. Multivariate analysis indicated that male recipient sex was a risk factor for post-LT survival (HR = 1.381, P = 0.046). Among the donor-recipient transplant patterns, the male-male donor-recipient transplant pattern was associated with the poorest post-LT survival (P < 0.05). Conclusions: Our findings highlighted that the post-LT outcomes of female recipients were significantly superior to those of male recipients, and the male-male donor-recipient transplant pattern was associated with the poorest post-LT survival. Livers from male donors may provide the most benefit to female recipients. Our results indicate that sex should be considered as a critical factor in organ allocation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China

Chen,

Yang,

Gao

et al. 2024

Cancer Biol Med

View full text Add to dashboard Cite

show abstract

“…The urgency for liver transplantation, particularly in patients with cancer, is represented by the MELD-system only for standard exceptions. patients, whose only curative treatment option is liver transplantation, would die of disease progression or be excluded from liver transplantation by progression before they were allocated an organ by the prevailing allocation system [30,[36][37][38][39][40]. Thus, living liver donation is a great opportunity for this patient cohort.…”

Section: Discussionmentioning

confidence: 99%

Effective Living Donor Evaluation in a Western Liver Transplantation Program

Rohland

2024

Preprint

View full text Add to dashboard Cite

BackgroundLiving donor liver transplantation offers comparable long-term results to cadaveric donor transplantation. This study analyzes the selection process of living liver donors at a Western transplant center that utilizes both donation forms. MethodsThis retrospective analysis examined potential living donors, collecting medical data and reasons for refusal, and divided patients by indication and urgency for transplantation. ResultsFrom January 2013 to December 2023, 594 potential living donors were assessed at Jena University Hospital. Of these, 124 living donor transplants were performed. During outpatient evaluation, 357 potential donors were excluded. Subsequently, 238 individuals underwent inpatient assessment, with 100 more being excluded. Main reasons for donor refusal included medical or psychological issues (n=160), disease progression in recipients (n=90), and recipient refusal or donor withdrawal (n=54). The evaluation process showed a trend towards considering more distant relatives and acquaintances as donor candidates with increasing severity of the recipient's disease.

show abstract

“…Hepatocellular carcinoma (HCC) is among the most common malignant tumors, causing substantial numbers of tumor-related deaths worldwide 1 , 2 . Surgery is the principal method of obtaining a radical cure, including hepatectomy and liver transplantation 3 , 4 . However, most HCC patients are diagnosed when in middle or late disease stages, which are characterized by a large tumor burden, vessel invasion, extra-hepatic metastasis, and poor liver function, etc 5 .…”

Section: Introductionmentioning

confidence: 99%

Caffeic acid phenethyl ester derivative exerts remarkable anti-hepatocellular carcinoma effect, non-inferior to sorafenib, in vivo analysis

Gong,

Wang,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Caffeic acid phenethyl ester (CAPE) and its derivatives exhibit considerable effects against hepatocellular carcinoma (HCC), with unquestioned safety. Here we investigated CAPE derivative 1ʹ (CAPE 1ʹ) monotherapy to HCC, compared with sorafenib. HCC Bel-7402 cells were treated with CAPE 1ʹ, the IC50 was detected using CCK-8 analysis, and acute toxicity testing (5 g/kg) was performed to evaluate safety. In vivo, tumor growth after CAPE 1ʹ treatment was evaluated using an subcutaneous tumor xenograft model. Five groups were examined, with group 1 given vehicle solution, groups 2, 3, and 4 given CAPE 1ʹ (20, 50, and 100 mg/kg/day, respectively), and group 5 given sorafenib (30 mg/kg/day). Tumor volume growth and tumor volume-to-weight ratio were calculated and statistically analyzed. An estimated IC50 was 5.6 µM. Acute toxicity tests revealed no animal death or visible adverse effects with dosage up to 5 g/kg. Compared to negative controls, CAPE 1ʹ treatment led to significantly slower increases of tumor volume and tumor volume-to-weight. CAPE 1ʹ and sorafenib exerted similar inhibitory effects on HCC tumors. CAPE 1ʹ was non-inferior to sorafenib for HCC treatment, both in vitro and in vivo. It has great potential as a promising drug for HCC, based on effectiveness and safety profile.

show abstract

Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective

Cited by 11 publications

References 65 publications

Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China

Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China

Effective Living Donor Evaluation in a Western Liver Transplantation Program

Caffeic acid phenethyl ester derivative exerts remarkable anti-hepatocellular carcinoma effect, non-inferior to sorafenib, in vivo analysis

Contact Info

Product

Resources

About